ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;88:924-928. doi:10.1016/j.athoracsur.2009.05.039
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sebastian A. Defranchi
Stephen D. Cassivi
Francis C. Nichols
Mark S. Allen
Claude Deschamps
Dennis A. Wigle
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Defranchi, S. A.
Right arrow Articles by Wigle, D. A.
PubMed
Right arrow Articles by Defranchi, S. A.
Right arrow Articles by Wigle, D. A.
Related Collections
Right arrow Lung - cancer
Right arrowRelated Article

Original Articles: General Thoracic

N2 Disease in T1 Non-Small Cell Lung Cancer

Sebastian A. Defranchi, MD, Stephen D. Cassivi, MD, MS, Francis C. Nichols, MD, Mark S. Allen, MD, K. Robert Shen, MD, Claude Deschamps, MD, Dennis A. Wigle, MD, PhD*

Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota

Accepted for publication May 13, 2009.

* Address correspondence to Dr Wigle, Division of General Thoracic Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Email: wigle.dennis{at}mayo.edu).

Presented at the Poster Session of the Forty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Francisco, CA, Jan 26–28, 2009. Winner of the Blue Ribbon as the top General Thoracic Poster.

Background: The optimal management strategy for mediastinal staging in early-stage non-small cell lung cancer (NSCLC) is not clearly defined. The true prevalence of mediastinal lymph node metastases (N2 disease) in resected pathologic T1 (pT1) NSCLC must be known to define the role of invasive mediastinal staging in these patients.

Methods: Data of patients with pT1 lesions resected at Mayo Clinic between 1998 and 2006 were retrospectively reviewed. Patients with N2 disease were identified from pathology and operative reports. We reviewed demographics, radiologic data, and surgical procedures for those with pathologic T1 N2 NSCLC.

Results: We identified 968 cases of pT1 lesions, 59 with pN2 disease (6.1%). For those with T1 N2 disease, the primary lung lesion was peripheral in 18 (31%) and central in 41 (69%). Of these, 36 had negative non-invasive mediastinal staging (3.7%) and were incidentally discovered. The most frequently affected lymph node station was 7 in 22 patients (37%), followed by 5,6 in 18 (31%). Mediastinoscopy found positive lymph nodes in 3 of 16 patients (19%) in which it was performed. Overall 5-year survival for pT1 N2 incidentally discovered during mediastinal lymph node dissection at the time of lung resection was 46% (95% confidence interval, 31% to 68%).

Conclusions: True pT1 NSCLC harbors a relatively low rate of N2 disease. The rate of occult N2 disease not observed on noninvasive preoperative mediastinal staging is even lower. For patients with T1 NSCLC and negative mediastinal imaging, routine mediastinoscopy results in a low yield of occult N2 disease discovery.


Related Article

Invited Commentary
Stephen C. Yang
Ann. Thorac. Surg. 2009 88: 928-929. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
S. C. Yang
Invited commentary.
Ann. Thorac. Surg., September 1, 2009; 88(3): 928 - 929.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.